Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Quarterly report · Q3

9776.TEDINET S100SUF0
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥14.9bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥20.1bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥15.3bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥415m2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥817m2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥418m2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥1.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥972m2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥508m2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥891m2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥312m2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥569m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥493m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥305m2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥578m2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥16.9bnat 2023-12-31Cons.Assets
Total assets¥16.5bnat 2023-03-31Cons.Assets
Total assets¥16.9bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥5.8bnat 2023-12-31Cons.Liabilities
Total liabilities¥5.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥11.1bnat 2023-12-31Cons.Net assets
Net assets / equity¥10.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥10.8bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥4.0bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥3.7bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥93.672023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥25.722023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥170.532022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥147.852022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥70.532022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio64.0%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio64.1%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.2%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-12-31¥92m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-12-31¥90m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-12-31¥3m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-12-31¥66m
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥5.8bn
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥5.8bn
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥104m
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥8.3bn
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥8.3bn
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥548m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥1.2bn
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥722m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥477m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2023-04-01 → 2023-12-31−¥7m
—segment totalrevenue2023-04-01 → 2023-12-31¥15.2bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥14.8bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥477m
—segment totalsegment profit2023-04-01 → 2023-12-31¥645m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥14.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-12-31¥480m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥711m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥75m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥73m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥3m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31¥49m
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥6.4bn
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥6.4bn
jpcrp040300-q3r_E04950-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥532m
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥8.0bn
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥8.0bn
jpcrp040300-q3r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥601m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥1.2bn
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥726m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥495m
jpcrp040300-q3r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2022-04-01 → 2022-12-31−¥8m
—segment totalrevenue2022-04-01 → 2022-12-31¥15.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥15.2bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥495m
—segment totalsegment profit2022-04-01 → 2022-12-31¥1.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥15.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥498m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥1.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 389
ItemContextValueUnit
Net defined benefit liabilityPrior1YearInstant18639000JPY
Net defined benefit liabilityCurrentQuarterInstant21265000JPY
Long term accounts payable otherPrior1YearInstant90414000JPY
Long term accounts payable otherCurrentQuarterInstant85814000JPY
Deferred tax liabilitiesPrior1YearInstant16594000JPY
Deferred tax liabilitiesCurrentQuarterInstant9491000JPY
Other nclPrior1YearInstant20483000JPY
Other nclCurrentQuarterInstant63953000JPY
Noncurrent liabilitiesPrior1YearInstant2383779000JPY
Noncurrent liabilitiesCurrentQuarterInstant2242864000JPY
LiabilitiesPrior1YearInstant5640294000JPY
LiabilitiesCurrentQuarterInstant5833202000JPY
Capital stockPrior1YearInstant983350000JPY
Capital stockCurrentQuarterInstant983350000JPY
Capital surplusPrior1YearInstant1015270000JPY
Capital surplusCurrentQuarterInstant1015270000JPY
Retained earningsPrior1YearInstant9304184000JPY
Retained earningsCurrentQuarterInstant9539553000JPY
Treasury stockPrior1YearInstant-757451000JPY
Treasury stockCurrentQuarterInstant-757451000JPY
Shareholders equityPrior1YearInstant10545353000JPY
Shareholders equityCurrentQuarterInstant10780721000JPY
Valuation difference on available for sale securitiesPrior1YearInstant40044000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant64920000JPY
Valuation and translation adjustmentsPrior1YearInstant40044000JPY
Valuation and translation adjustmentsCurrentQuarterInstant64920000JPY
Non controlling interestsPrior1YearInstant295588000JPY
Non controlling interestsCurrentQuarterInstant256176000JPY
Net assetsPrior1YearInstant10880986000JPY
Net assetsCurrentQuarterInstant11101818000JPY
Liabilities and net assetsPrior1YearInstant16521281000JPY
Liabilities and net assetsCurrentQuarterInstant16935020000JPY
Net salesPrior1YTDDuration15250105000JPY
Net salesCurrentYTDDuration14852697000JPY
Cost of salesPrior1YTDDuration10426960000JPY
Cost of salesCurrentYTDDuration10399934000JPY
Gross profitPrior1YTDDuration4823144000JPY
Gross profitCurrentYTDDuration4452762000JPY
Selling general and administrative expensesPrior1YTDDuration4006180000JPY
Selling general and administrative expensesCurrentYTDDuration4038125000JPY
Operating incomePrior1YTDDuration816964000JPY
Operating incomeCurrentYTDDuration414637000JPY
Interest income noiPrior1YTDDuration132000JPY
Interest income noiCurrentYTDDuration110000JPY
Dividends income noiPrior1YTDDuration5082000JPY
Dividends income noiCurrentYTDDuration5023000JPY
Rent income noiPrior1YTDDuration30659000JPY
Rent income noiCurrentYTDDuration30287000JPY
Subsidy income noi bountyPrior1YTDDuration146072000JPY
Subsidy income noi bountyCurrentYTDDuration17477000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass